Merck & Co. stock (US58933Y1055): Oncology portfolio advances at ASCO 2026

Merck highlighted new long-term data and pipeline advancements across its oncology portfolio at ASCO 2026, reinforcing the clinical impact of KEYTRUDA and strengthening its competitive position in cancer therapeutics.

Merck & Co. presented new long-term data and oncology pipeline advancements at the American Society of Clinical Oncology (ASCO) 2026 conference, underscoring the durability and clinical value of its anti-PD-1 therapy KEYTRUDA (pembrolizumab) across multiple tumor types, according to Merck press release as of May 2026. The data reinforce the long-term impact of KEYTRUDA and Merck's rapidly advancing pipeline, positioning the company as a leader in oncology innovation for US investors tracking large-cap pharmaceutical exposure.

As of: May 12, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck & Co., Inc.
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Rahway, New Jersey, United States
• Core markets: Oncology, immunology, infectious disease, vaccines
• Key revenue drivers: KEYTRUDA (pembrolizumab), oncology portfolio, pipeline advancement
• Home exchange/listing venue: NYSE (MRK)
• Trading currency: USD

Merck & Co.: core business model

Merck & Co. operates as a global pharmaceutical and biotechnology company with a primary focus on oncology, immunology, infectious disease, and vaccines. The company is known as MSD outside the United States and Canada. Merck's business model centers on the discovery, development, and commercialization of prescription medicines and vaccines, with KEYTRUDA serving as a cornerstone asset in its oncology franchise. The company invests heavily in research and development to advance its pipeline and maintain competitive positioning in high-value therapeutic areas.

KEYTRUDA and oncology portfolio strength

KEYTRUDA (pembrolizumab), Merck's anti-PD-1 immunotherapy, remains central to the company's growth strategy and revenue generation. The presentation of new long-term data at ASCO 2026 reinforces clinical efficacy across multiple tumor types and supports continued adoption in both first-line and advanced settings. Merck's rapidly advancing pipeline includes additional oncology candidates designed to address unmet medical needs and expand treatment options for cancer patients. This portfolio depth provides multiple revenue streams and reduces dependence on any single asset, a key consideration for institutional and retail investors evaluating pharmaceutical sector exposure.

Conclusion

Merck & Co.'s presentation of new long-term oncology data at ASCO 2026 reinforces the clinical durability of KEYTRUDA and the strength of its pipeline, supporting its position as a leading player in cancer therapeutics. For US investors, Merck represents exposure to a diversified pharmaceutical portfolio with significant revenue generation from established assets and growth potential from pipeline advancement. The company's continued investment in oncology innovation and data presentation at major medical conferences underscores its commitment to maintaining competitive advantage in high-value therapeutic markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.